221 related articles for article (PubMed ID: 35434961)
21. Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.
Kukafka R; Pan S; Silverman T; Zhang T; Chung WK; Terry MB; Fleck E; Younge RG; Trivedi MS; McGuinness JE; He T; Dimond J; Crew KD
JAMA Netw Open; 2022 Jul; 5(7):e2222092. PubMed ID: 35849397
[TBL] [Abstract][Full Text] [Related]
22. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Shulman LP
Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
[TBL] [Abstract][Full Text] [Related]
23. Implementing digital systems to facilitate genetic testing for hereditary cancer syndromes: An observational study of 4 clinical workflows.
Wang C; Lu H; Bowen DJ; Xuan Z
Genet Med; 2023 May; 25(5):100802. PubMed ID: 36906849
[TBL] [Abstract][Full Text] [Related]
24. Adherence to guidelines for the referral of patients with colorectal cancer and abnormal tumour tissue testing for assessment of Lynch syndrome.
Han J; Spigelman AD
ANZ J Surg; 2019 Oct; 89(10):1281-1285. PubMed ID: 30856687
[TBL] [Abstract][Full Text] [Related]
25. Validation of a digital identification tool for individuals at risk for hereditary cancer syndromes.
Bucheit L; Johansen Taber K; Ready K
Hered Cancer Clin Pract; 2019; 17():2. PubMed ID: 30651894
[TBL] [Abstract][Full Text] [Related]
26. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Daly MB; Pilarski R; Berry M; Buys SS; Farmer M; Friedman S; Garber JE; Kauff ND; Khan S; Klein C; Kohlmann W; Kurian A; Litton JK; Madlensky L; Merajver SD; Offit K; Pal T; Reiser G; Shannon KM; Swisher E; Vinayak S; Voian NC; Weitzel JN; Wick MJ; Wiesner GL; Dwyer M; Darlow S
J Natl Compr Canc Netw; 2017 Jan; 15(1):9-20. PubMed ID: 28040716
[TBL] [Abstract][Full Text] [Related]
27. Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian.
Hessock M; Brewer T; Hutson S; Anderson J
Nurs Womens Health; 2021 Jun; 25(3):187-197. PubMed ID: 33933425
[TBL] [Abstract][Full Text] [Related]
28. Molecular Features and Clinical Management of Hereditary Gynecological Cancers.
Ueki A; Hirasawa A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33327492
[TBL] [Abstract][Full Text] [Related]
29. Missed opportunities: Genetic counseling and testing among an ethnically diverse cohort of women with endometrial cancer.
Lee J; Gubernick LR; Brodsky AL; Fehniger JE; Levine DA; Gerber D; Asgari SA; Cantor A; Martineau JT; Ginsburg OM; Smith JA; Pothuri B
Gynecol Oncol; 2018 Oct; 151(1):153-158. PubMed ID: 30077346
[TBL] [Abstract][Full Text] [Related]
30. Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
Beebe-Dimmer JL; Kapron AL; Fraser AM; Smith KR; Cooney KA
J Clin Oncol; 2020 Jun; 38(16):1807-1813. PubMed ID: 32208047
[TBL] [Abstract][Full Text] [Related]
31. Genetic counseling and cascade genetic testing in Lynch syndrome.
Hampel H
Fam Cancer; 2016 Jul; 15(3):423-7. PubMed ID: 26969309
[TBL] [Abstract][Full Text] [Related]
32. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
33. An investigation of genetic counselors' testing recommendations: pedigree analysis and the use of multiplex breast cancer panel testing.
Lundy MG; Forman A; Valverde K; Kessler L
J Genet Couns; 2014 Aug; 23(4):618-32. PubMed ID: 24569857
[TBL] [Abstract][Full Text] [Related]
34. Risk assessment and genetic counseling for Lynch syndrome - Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer.
Holter S; Hall MJ; Hampel H; Jasperson K; Kupfer SS; Larsen Haidle J; Mork ME; Palaniapppan S; Senter L; Stoffel EM; Weissman SM; Yurgelun MB
J Genet Couns; 2022 Jun; 31(3):568-583. PubMed ID: 35001450
[TBL] [Abstract][Full Text] [Related]
35. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
[TBL] [Abstract][Full Text] [Related]
36. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors.
Berliner JL; Fay AM;
J Genet Couns; 2007 Jun; 16(3):241-60. PubMed ID: 17508274
[TBL] [Abstract][Full Text] [Related]
37. The identification of Lynch syndrome in British Columbia.
Cremin CM; Armstrong L; Gill S; Huntsman D; Bajdik C
Can J Gastroenterol; 2009 Nov; 23(11):761-7. PubMed ID: 19893772
[TBL] [Abstract][Full Text] [Related]
38. Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines.
Kotnik U; Peterlin B; Lovrecic L
BMC Cancer; 2021 Jun; 21(1):665. PubMed ID: 34082720
[TBL] [Abstract][Full Text] [Related]
39. PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing?
Mester JL; Moore RA; Eng C
Oncologist; 2013; 18(10):1083-90. PubMed ID: 24037976
[TBL] [Abstract][Full Text] [Related]
40. Hereditary cancer syndromes, their testing and prevention.
Foretová L
Cas Lek Cesk; 2019; 158(1):15-21. PubMed ID: 31046387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
